Trial Profile

A Phase II Study of TAS-102 in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tipiracil/trifluridine (Primary)
Indications Bladder cancer; Carcinoma; Urogenital cancer
Focus Therapeutic Use

Most Recent Events

04 Mar 2024 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified March 2022).
09 Mar 2022 Planned primary completion date changed from 1 Jul 2021 to 1 Jul 2023.
30 Jan 2019 Planned End Date changed from 1 Dec 2023 to 1 Jan 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com